Login / Signup

Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis.

Amir TavakkolJanet C DuBoisAditya Kumar Gupta
Published in: Antimicrobial agents and chemotherapy (2024)
This study is registered with ClinicalTrials.gov as NCT03244280.
Keyphrases
  • study protocol
  • clinical trial
  • phase iii
  • early onset
  • phase ii
  • resistance training
  • randomized controlled trial
  • body composition
  • open label
  • solid state